Trials / Terminated
TerminatedNCT01193491
Dose Escalation of IPI-493 in Hematologic Malignancies
A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies With Client Proteins of Hsp90
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Infinity Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IPI-493 | Capsules, ascending dose, multiple schedules |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-09-02
- Last updated
- 2015-04-15
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01193491. Inclusion in this directory is not an endorsement.